Full-Time

Finance Business Partner North America Commercial Operations

Commercial Finance Business Partnering

Posted on 8/22/2025

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

Compensation Overview

$200k - $225k/yr

+ Incentive Compensation + Equity

Summit, NJ, USA

Hybrid

Hybrid work arrangement indicated by #LI-Hybrid.

Category
Finance & Banking (1)
Required Skills
Power BI
SAP Products
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Bachelor degree in Accounting, Finance or related discipline; MBA or other advanced degree in related field desirable
  • Professional certification (CPA / CA, ACA, ACCA, CIMA) preferred
  • 10+ years experience in accounting, finance or similar roles including financial analytics and planning
  • 3+ years in commercial finance in a business facing role where there is demonstrated understanding of the value chain in the US life sciences preferred
  • Demonstrated leadership experience including influencing senior management and critical stakeholders
  • Expert level Excel incl. data analysis functionality, good skills in other MS-Office applications; SAP and Business Intelligence / Financial Consolidation applications (e.g. BW/BI, SAP BPC, SAC) including Power BI. Model N would be advantageous.
Responsibilities
  • Trusted advisor to VP Commercial North America to develop strategies, ensuring financial plans align with goals
  • Primary finance partner providing insights and guidance on budgets, forecasts, and resource allocation
  • Contribute to the development of budget and forecasts, identifying opportunities for cost optimization while maintaining strategic focus
  • Provide proactive, data-driven financial insights to support critical decisions
  • Be a trusted advisor to Commercial leaders, offering financial recommendations on product pricing and channel strategies to maximize impact and profitability
  • Manage economic research e.g. market and competitor analysis, and financial modelling to provide reports and recommendations to management
  • Perform complex financial modelling and analysis for strategic and operational decision support
  • Oversee the budget and forecast process, ensuring accuracy and reporting of important financial metrics
  • Provide ongoing financial analysis to monitor spend and assess its effectiveness in driving outcomes
  • Develop financial measurements, tracking performance against targets, and making recommendations for adjustments as needed
  • Understanding key drivers of US gross to net adjustments (c.$250m), preparing analysis to support month end accruals, as well as supporting the financial audit process. Includes approval of gross to net payments in Model N
  • Provide external financial audit support at half-year and full year, including preparation of documentation and analysis, and working with auditors to provide business insight for items as requested and resolution of issues raised observing agreed timelines
  • Support ensuring that financial processes follow CSL policies and that proper controls are in place, as applicable
  • Advise on alternate financial plans and potential impact of current and future laws and regulations
  • Manage team, providing guidance and professional development opportunities
  • Foster a collaborative environment that inspires results.
Desired Qualifications
  • MBA or other advanced degree in related field desirable
  • Professional certification (CPA / CA, ACA, ACCA, CIMA) preferred
  • 3+ years in commercial finance in a business facing role where there is demonstrated understanding of the value chain in the US life sciences preferred
  • Model N would be advantageous.

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Simplify Jobs

Simplify's Take

What believers are saying

  • HEMGENIX gene therapy sustains 37% factor IX levels through four years post-2025 data.
  • KOSTAIVE self-amplifying mRNA COVID vaccine approved by EC February 2025.
  • VarmX $2.2B acquisition option expands bleeding disorder pipeline in 2026.

What critics are saying

  • Seqirus separation triggers $500M charges and 14% revenue loss from Pentagon mandate scrap.
  • Grifols opens 20 plasma centers by 2027, eroding CSL Behring's immunoglobulin share.
  • Novartis Fabhalta displaces CSL Vifor's $1.5B nephrology revenues within 12 months.

What makes CSL unique

  • CSL Behring leads plasma-derived therapies for haemophilia and immunodeficiencies.
  • CSL Seqirus dominates influenza vaccines with global production scale.
  • CSL Vifor specializes in iron deficiency and nephrology treatments post-2022 acquisition.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at CSL who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

3%
USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...

Stock Titan
Aug 1st, 2025
Automated Logic Acquires Control Solutions Ltd.

Automated Logic – Canada, Ltd. (ALC), part of Carrier Global Corporation, has acquired Control Solutions, Ltd. (CSL), an independent provider of building-automation systems in Coquitlam, British Columbia. This acquisition establishes ALC's first field office in Vancouver, expanding its presence in Western Canada and enhancing its ability to deliver intelligent building solutions in high-growth sectors across British Columbia.

PharmiWeb.com
Apr 14th, 2025
First Patient Treated With Hemgenix® (Etranacogene Dezaparvovec) Gene Therapy For Haemophilia B In Austria

Vienna, Austria – 9 April 2025 - CSL Behring Austria today announced that the first haemophilia B patient in Austria was treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at the Comprehensive Care Center of the University Hospital of Medicine Vienna.HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1“It is a great opportunity for people with hemophilia B to live a symptom-free life for many years,” explains hematologist Univ.-Prof. Priv.-Doz. Dr Cihan Ay from the Medical University of Vienna, University Clinic for Internal Medicine I Clinical Department for Hematology and Hemostaseology."For the community of affected patients and their families, this represents an enormously significant milestone: the ability to treat hemophilia with gene therapy, and the fact that this option is now available in Austria, is something our community has been eagerly anticipating and hoping for over decades," says Thomas Schindl, MA, Chairman of the Austrian Hemophilia Society (ÖHG)."We are proud and grateful to offer haemophilia B patients in Austria a treatment option that has the potential to transform their lives," said Dr Beate Natmessnig, Managing Director of CSL Behring Austria. "This achievement is the result of outstanding regional and national collaboration among all parties involved and is a strong testament to Austria's innovative capabilities."HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022

PharmiWeb.com
Apr 3rd, 2025
Csl Behring And Gkv-Spitzenverband Agree On Reimbursement Price For Hemgenix® – Europe'S First Gene Therapy For Haemophilia B

Marburg, Germany, 2 April 2025 – CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX®. This agreement marks the availability of the first gene therapy approved in Europe for haemophilia B under an innovative, national, success-based reimbursement model, being implemented for the first time in Germany.HEMGENIX® represents significant progress in the treatment of haemophilia B. The aim of this one-time gene therapy is to eliminate the need for regular factor IX infusions, thereby offering patients the possibility of more freedom from prophylaxis and significantly improving their quality of life.1-4 This development not only provides substantial relief for those affected but also has the potential to reduce long-term costs for the healthcare system.‘The performance-based payment model at national level which was agreed with the GKV-Spitzenverband is unique in Germany. It addresses key reimbursement challenges, such as the question of long-term efficacy, which is inherent for any one-time therapy. Reimbursement is linked to treatment success of the individual patient,’ explains Stefan Neudoerfer, CSL Behring's chief negotiator in Germany.Moreover, this reimbursement model reflects the high therapeutic and innovative value of HEMGENIX® and sets new standards for integrating innovative gene therapies into the German healthcare system.‘The agreement on the reimbursement price of HEMGENIX® is a decisive step for the care of people with haemophilia B in Germany. It enables access to a groundbreaking therapy and recognises the long-term medical and economic benefits of gene therapy,’ explains Christian Wieszner, Managing Director of CSL Behring Germany.With this agreement, CSL Behring is underlining its commitment to innovative therapies that sustainably improve the lives of patients

INACTIVE